http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102169256-B1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-19 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19 |
filingDate | 2018-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2020-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2020-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-102169256-B1 |
titleOfInvention | Anticancer composition comprising bladder cancer cell line-derived autocrine motility factor as effective component |
abstract | The present invention relates to an anticancer composition containing AMF derived from a bladder cancer cell line as an active ingredient, and more particularly, the AMF derived from a bladder cancer cell line of the present invention inhibits the proliferation of colon cancer or laryngeal cancer and has an excellent effect of causing apoptosis. , The composition of the present invention containing AMF derived from a bladder cancer cell line as an active ingredient can be used as an anticancer agent. |
priorityDate | 2018-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1002.